Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Delta Air Lines

Occidental Petroleum

For much of 2022 and 2023, investors could take shelter in dividend stocks. They were, as the saying goes, the best houses in a bad neighborhood (the equity markets).

3 Strong-Buy Dividend Stocks That Analysts Love

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the ‘Company') will hold an Enterprise Business Review for the investment community on Tuesday, December 5, 2023. During the event, Company leaders will share a detailed review of the Innovative Medicine and MedTech businesses and their respective pipelines as well as discuss the Company's long-term strategy to deliver sustained growth and value to shareholders. Following the ringing of the Opening Bell at the New York Sto.

Johnson & Johnson to Host Enterprise Business Review

CVRx

Legend Biotech

Protagonist Therapeutics

J&J's biggest position is in a biotech that's developing cancer cell therapies. The healthcare giant's second-largest stake is in a medical device maker that focuses on heart failure.

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Bristol-Myers

Eli Lilly

Pfizer

VanEck Vectors Pharmaceutical ETF

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Atmos Energy

Coca-Cola

NextEra Energy

Sysco

Target

With the possibility that the fourth quarter's economic results might disappoint given the stellar print of Q3, investors may want to consider dividend aristocrats. If you're looking for some of the best dividend stocks for income, you can't go wrong with this label.

Storm-Proof Income: 7 Dividend Aristocrats to Fortify Your Portfolio

General Motors

Procter & Gamble

Berkshire Hathaway revealed the status of the stakes it currently has in various companies in a Tuesday disclosure it submitted to the Securities and Exchange Commission.

Berkshire sheds GM, Johnson & Johnson, Procter & Gamble as it amasses cash

Celanese

Mondelez

Microsoft

Amazon

Chevron

Liberty Media Corp-Liberty Formula One

Globe Life Inc

Markel

Warren Buffett dumped GM, Procter & Gamble and a number of other blue chip names in Q3.

14 Stocks Warren Buffett Is Selling (and 1 He's Buying)

CVS Health

CVS Health's guidance cuts are weighing on the stock, but there are good reasons to buy now. Johnson & Johnson still faces legal issues, none of which look likely to derail its long-term goals.

2 Dividend Stocks Near Their 52-Week Lows to Buy and Hold Forever

Berkshire Hathaway (NYSE: BRKA, BRKB) announced to the Security and Exchange Commission (SEC) its Q3 re port on Tuesday, November 14, which tells an interesting story of new acquisitions, reductions, and exits from holdings.

Here's Warren Buffett's stock portfolio changes

Big holdings in Apple, Bank of America and Coca-Cola were unchanged.

Warren Buffett's Berkshire Hathaway Sells Off GM. These Stocks Also Got the Boot.

Warren Buffett's company sold a bunch of stocks and made at least one confidential bet last quarter. Berkshire Hathaway exited long-held stakes in GM, J&J, P&G, UPS and Mondelez.

Warren Buffett's Berkshire Hathaway reveals it sold a bunch of long-held stocks - and made at least one secret bet

Genuine Parts

West Pharmaceutical Services

Need help boosting your long-term portfolio gains? Well, you're in luck.

Blue-Chip Bargains: Top 3 Oversold Aristocrats for Value Investors

Medtronic

If you're a dividend investor, there is nothing more attractive than dividend aristocrats, those S&P 500 companies that have increased their annual dividend payment for 25 consecutive years or more.  A recent article about two dividend stocks trading near 52-week lows got me thinking about the dividend aristocrats and possible opportunities to buy them at or near 52-week lows.

It's Time to Buy These 3 Dividend Aristocrats Trading Near 52-Week Lows

Berkshire's stock portfolio is concentrated in five companies: Apple, Bank of America, American Express, Coca-Cola and Chevron.

Warren Buffett's Berkshire Hathaway Sheds Investments in GM, J&J, P&G

British American Tobacco

iShares Core High Dividend ETF

Hershey

Kimberly-Clark

Realty Income Corp

PepsiCo

Philip Morris

iShares 20+ Year Treasury Bond ETF

Consumer Staples Select Sector SPDR Fund

Dividend investing is struggling in the current macroeconomic environment due to high interest rates. The yield on T-Bonds disincentivizes investors from buying dividend companies, leading to a drop in their performance. Exceptions to this trend include investments with a high dividend yield on cost, undervalued companies with potential for capital gains, and companies with rapid growth in earnings and dividends.

All Dividend Companies Have One Big Problem In Common

AbbVie

These dividend stocks each have a solid track record of dividend growth, and their dividend yield tops that of the S&P 500 index. These players also offer promising earnings prospects.

3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing

Novo Nordisk

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

4 Large Drug Stocks Likely to Sail Through Industry Woes

Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its consumer health unit.

Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth

Emerson Electric

With November here, many investors are looking toward Thanksgiving, the holidays, and the end of the year.

News for Johnson & Johnson Stock (JNJ)